Patent classifications
A61K39/36
Process for preparing vaccine composition
A method of preparing a composition comprising one or more antigens adsorbed to an amino acid wherein said method comprises: (i) mixing a solution of one or more antigens with a solution of the amino acid in an aqueous acid whilst neutralizing the mixture of solutions, thereby forming an adsorbate comprising the one or more antigens and the amino acid; (ii) separating the adsorbate into a desired buffer by cross-flow filtration thereby forming said composition; and (iii) recovering said composition; wherein steps (i) to (iii) are performed in a sterile environment and within a closed system.
Process for preparing vaccine composition
A method of preparing a composition comprising one or more antigens adsorbed to an amino acid wherein said method comprises: (i) mixing a solution of one or more antigens with a solution of the amino acid in an aqueous acid whilst neutralizing the mixture of solutions, thereby forming an adsorbate comprising the one or more antigens and the amino acid; (ii) separating the adsorbate into a desired buffer by cross-flow filtration thereby forming said composition; and (iii) recovering said composition; wherein steps (i) to (iii) are performed in a sterile environment and within a closed system.
Reduction of in vitro genotoxicity of pollen extracts by removal of flavonoids
The invention relates to grass pollen extracts containing reduced amount of flavonoid glycosides in order to minimize the risks of genotoxicity of the grass pollen extracts. The invention also relates to a method of preparing grass pollen extracts containing reduced amount of flavonoid glycosides by ultrafiltration. Flavonoid glycosides are naturally present in grass pollen extracts and they have been identified as being responsible for the formation of flavonoid aglycones, which are genotoxic in vitro, under the influence of enzymes contained in the grass pollen extracts.
Reduction of in vitro genotoxicity of pollen extracts by removal of flavonoids
The invention relates to grass pollen extracts containing reduced amount of flavonoid glycosides in order to minimize the risks of genotoxicity of the grass pollen extracts. The invention also relates to a method of preparing grass pollen extracts containing reduced amount of flavonoid glycosides by ultrafiltration. Flavonoid glycosides are naturally present in grass pollen extracts and they have been identified as being responsible for the formation of flavonoid aglycones, which are genotoxic in vitro, under the influence of enzymes contained in the grass pollen extracts.
Horse allergen and methods
A method for performing in vitro diagnosis of type 1 allergy, comprises contacting an immunoglobulin-containing body fluid sample from a patient suspected of having Type 1 allergy with an immobilized horse allergen immobilized on a solid support, and detecting the presence, in the sample, of IgE antibodies specifically binding to the horse allergen, wherein the presence of such IgE antibodies specifically binding to the horse allergen is indicative of Type 1 allergy. A method for treatment of Type 1 allergy comprises administering to an individual susceptible to such treatment, the horse allergen, or a form of the horse allergen that is modified to abrogate or attenuate its IgE binding response. The horse allergen may be produced via a vector and a host cell comprising the vector.
Methods and articles for preventing or reducing risk of developing a hyperallergenic immune system
Infant pacifiers, compositions, and methods of use thereof, for preventing or reducing risk of developing a hyperallergenic immune system or allergic condition are provided.
Methods and articles for preventing or reducing risk of developing a hyperallergenic immune system
Infant pacifiers, compositions, and methods of use thereof, for preventing or reducing risk of developing a hyperallergenic immune system or allergic condition are provided.
Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses
Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen in some embodiments.
Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses
Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen in some embodiments.
Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses
Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen in some embodiments.